# First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

> **NCT06370663** · PHASE2 · TERMINATED · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 1 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** HAIC (GEMOX)
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06370663
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study was terminated due to unacceptable treatment-related toxicity that raised safety concerns and outweighed the potential benefits.
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06370663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06370663, "First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06370663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*